Abstract
Abstract TGF-β type III receptor (TGFBR3), a co-receptor for TGF-β family members, is required for the high-affinity binding of ligands to their receptors to begin their cellular function. More and more studies showed contrasting roles of TGFBR3, tumor suppressor or oncogene, depending on the cancer type. However, the exact role of TGFBR3 and the responsible mechanism in oral cancer remains to be characterized. By using immunohisotochemical staining and real-time PCR, we found a down-regulation of TGFBR3 in oral cancer tissues. In the same line of this observation, we also detected a significant decrease of soluble TGFBR3 (sTGFBR3) in the oral cancer patient sera when compared with normal sera. Using Kaplan Meyer survival curve analysis and log rank test, we found that low TGFBR3 expression patients tend to have poor clinical outcome than those with high expression. Genetic manipulation of TGFBR3 was used to examine the role of TGFBR3 in oral cancer cells. Although the alteration resulted in differential effects on cell proliferation, TGFBR3 knockdown significantly increased migration and Matrigel invasion. TGFBR3 overexpression had the opposite effect on cell migration and invasion. Xenograft tumorigenesis and metastasis will be used to confirm the effect observed in vitro. Since TGFB is frequently overxpressed in oral cancer cells, we will evaluate the therapeutic potential of using sTGFBR3 in treating oral cancer in mice. Our study should facilitate studying the role of TGFBR3 in oral cancer progression and metastasis, and evaluating the possibility of using TGFBR3 as a therapeutic target for oral cancer treatment. Citation Format: Wei-Yu Fang, Jen-Ren Hsiao, Jang-Yang Chang, Sen-Tien Tsai, Li-Jin Hsu, Li-Wha Wu. Functional implication of TGFBR3 dysregulation and its clinical application in oral cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3987. doi:10.1158/1538-7445.AM2013-3987
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
